Another meta-analysis compared the efficacy and safety of two first-line therapies for unresectable hepatocellular carcinoma: anti-PD-1/L1 antibody plus anti-VEGF antibody, and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor. Here, VEGFA is linked to hepatocellular carcinoma.